The majority of the analysts thinks Biogen is currently underpriced. Currently the company is being followed by 14 analyst. The recommendations are: no sells, 8 times hold and 6 times buy. The average of the outstanding target prices for the stock is at 354,5 USD. This is approximately 15 percent more than the current price of 311,73 USD. Credit Suisse , Citigroup and Leerink Swann & Company recently provided recommendations for the stock.
Biogen 's market capitalization is based on the number of outstanding shares around 68,14 billion USD.
On Monday the stock closed at 311,73 USD.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.